Evaluation of ADMSC-fib Safety and Efficacy in the Treatment of Chronic Wounds

The primary objective of the study is to evaluate the **safety** and **efficacy** of ADMSC-fib in patients with **chronic wounds**. Chronic wounds are a significant clinical concern due to their prolonged healing time and potential for complications, impacting patient quality of life and healthcare resources. Assessing the safety and efficacy of ADMSC-fib could provide valuable insights into potential therapeutic options for managing these wounds.

The clinical trial involves participants diagnosed with **chronic wounds**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected without any specific lifestyle considerations such as diet, physical activity, or habits being highlighted. The sponsor has not disclosed any key inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the safety and efficacy of a treatment in patients with **chronic wounds**. This study is a Phase 4 trial, which typically involves post-marketing surveillance to gather additional information about the treatment's risks, benefits, and optimal use. The trial is structured as a randomized, double-blind, controlled study to ensure the reliability and validity of the results. The estimated duration of the trial spans from March 22, 2021, to June 22, 2025, allowing for comprehensive data collection and analysis.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a thorough evaluation to confirm the presence of chronic wounds and to ensure that participants meet all necessary inclusion criteria while not falling under any exclusion criteria. Following successful screening, participants will be randomly assigned to either the treatment or control group, with neither the participants nor the investigators aware of the group assignments, maintaining the double-blind nature of the study.

Throughout the trial, participants will attend regular follow-up visits at predetermined intervals. These visits are crucial for monitoring the participants' health, assessing the treatment's efficacy, and recording any adverse events. The frequency and specific timing of these visits will be determined by the study protocol, ensuring consistent data collection across all participants. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the long-term effects of the treatment and gather any remaining data.

The expected length of participant involvement will vary depending on the individual's enrollment date but will generally align with the overall trial duration. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with study procedures, or withdraw consent. The study's design and procedures are meticulously planned to ensure the collection of high-quality data while prioritizing participant safety and well-being.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy within the context of a Phase 4 study. The trial is scheduled to commence recruitment on March 22, 2021, with an estimated completion date of June 22, 2025. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology for measuring, collecting, and analyzing these efficacy parameters, adhering to the standards expected in a Phase 4 trial. The trial's design and execution will ensure that efficacy assessments are conducted systematically and in accordance with regulatory and scientific guidelines.